Plasma angiotensin-converting enzyme in alzheimer's disease

Journal of Alzheimer's Disease

Volumn 16, Issue 3, 2009, Pages 609-618

  Vardy, Emma R L C ^a,d   Rice, Penny J ^a   Bowie, Peter C W ^b   Holmes, John D ^c   Catto, Andrew J ^a,e   Hooper, Nigel M ^c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b SHEFFIELD HEALTH AND SOCIAL CARE NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e Airedale NHS Trust   (United Kingdom)

Author keywords

Alzheimer's disease; Angiotensin converting enzyme; Apolipoprotein E; Plasma; Shedding; Zinc metalloprotease

Indexed keywords

APOLIPOPROTEIN E4; DIPEPTIDYL CARBOXYPEPTIDASE; BIOLOGICAL MARKER; METALLOPROTEINASE; ZINC;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITION; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; BLOOD; GENETIC LINKAGE; GENETICS; GENOTYPE; METABOLISM; RISK FACTOR; ROC CURVE;

AGE OF ONSET; AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; FEMALE; GENOTYPE; HUMANS; LINKAGE (GENETICS); MALE; METALLOPROTEASES; PEPTIDYL-DIPEPTIDASE A; RISK FACTORS; ROC CURVE; ZINC;

EID: 65549110339     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-1002     Document Type: Article

References (46)

1. Mount C, Downton C (2006) Alzheimer disease: progress or profit? Nat Med 12, 780-784.
2. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81, 741-766.
3. Hama E, Saido TC (2005) Etiology of sporadic Alzheimer's disease: somatostatin, neprilysin, and amyloid-β peptide. Med Hypotheses 65, 498-500.
4. Carson JA, Turner AJ (2002) β-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J Neurochem 81, 1-8.
5. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S (2008) Aβ-degrading enzymes in Alzheimer's disease. Brain Pathol 18, 240-252.
6. Turner AJ, Hooper NM (2002) The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 23, 177-183.
7. Corvol P, Eyries M, Soubrier F (2004) Peptidyl-dipeptidase A/angiotensin I-converting enzyme. In Handbook of Prote-olytic Enzymes, Barrett AJ, Rawlings ND, Woessner JF, eds., Elsevier, Amsterdam, pp. 332-346.
8. Woodman ZL, Oppong SY, Cook S, Hooper NM, Schwager SLU, Brandt WF, Ehlers MRW, Sturrock ED (2000) Shedding of somatic angiotensin-converting enzyme(ACE)is inefficient comparedtotestis ACE despite cleavage at identical stalk sites. Biochem J 347, 711-718.
9. Oppong SY, Hooper NM (1993) Characterization of a sec-retase activity which releases angiotensin-converting enzyme from the membrane. Biochem J 292, 597-603.
10. Parvathy S, Hussain I, Karran EH, Turner AJ, Hooper NM (1998) Alzheimer's amyloid precursor protein a-secretase is inhibited by hydroxamic acid-based zinc metalloprotease inhibitors: similarities to the angiotensin converting enzyme secretase. Biochemistry 37, 1680-1685.
11. Parkin ET, Trew A, Christie G, Faller A, Mayer R, Turner AJ, Hooper NM (2002) Structure-activity relationship of hydroxamate-based inhibitors on the secretases that cleave the amyloid precursor protein, angiotensin converting enzyme, CD23, and pro-tumor necrosis factor-a. Biochemistry 41, 4972-4981.
12. Kehoe PG, Russ C, McIlory S, Williams H, Holmans P, Holmes C, Liolitsa D, Vahidassr D, Powell J, McGleenon B, Liddell M, Plomin R, Dynan K, Williams N, Neal J, Cairns NJ, Wilcock G, Passmore P, Lovestone S, Williams J, Owen MJ (1999) Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat Genet 21, 71-72.
13. Kehoe PG (2003) The renin-angiotensin-aldosterone system and Alzheimer's disease? J Renin Angiotensin Aldosterone Syst 4, 80-93.
14. Elkins JS, Douglas VC, JohnstonSC(2004) Alzheimer disease risk and genetic variation in ACE: a meta-analysis. Neurology 62, 363-368.
15. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic meta-analysesofAlzheimer disease genetic association studies: the AlzGene database. Nat Genet 39, 17-23.
16. HuJ, IgarashiA,Kamata M,Nakagawa H(2001) Angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide (Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 276, 47863-47868.
17. Oba R, Igarashi A, Kamata M, Nagata K,Takano S, Nakagawa H (2005) The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid β-peptide. Eur J Neurosci 21, 733-740.
18. Hemming ML, Selkoe DJ (2005) Amyloid β-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 280, 37644-37650.
19. Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, Fauq AH, Xiao HD, Bernstein KE, Eckman CB (2006) Regulation of steady-state β-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 281, 30471-30478.
20. Hemming ML, Selkoe DJ, Farris W (2007) Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis 26, 273-281.
21. Zou K, Yamaguchi H, Akatsu H, Sakamoto T, Ko M, Mi-zoguchi K, Gong JS, Yu W, Yamamoto T, Kosaka K, Yanagi-sawa K, Michikawa M(2007) Angiotensin- converting enzyme converts amyloid β-protein 1-42 (Aβ1-42) to Aβ1-40, and its inhibition enhances brain Aβ deposition. J Neurosci 27, 8628-8635.
22. Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ, Hooper NM (2006) Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension 48, 914-920.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
24. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
25. Teng EL, Chui HC (1987) The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 48, 314-318.
26. Foy CA, Rice GI, Ossei-Gerning N, Mansfield MW, Grant PJ (1997) Angiotensin-converting enzyme (ACE) gene polymorphisms in patients characterised by coronary angiography. Hum Genet 100, 420-425.
27. Catto AJ, McCormack LJ, Mansfield MW, Carter AM, Bam-ford JM, Robinson P, Grant PJ (2000) Apolipoprotein E polymorphism in cerebrovascular disease. Acta Neurol Scand 101, 399-404.
28. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90, 1977-1981.
29. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
30. Parvathy S, Karran EH, Turner AJ, Hooper NM (1998) The secretases that cleave angiotensin converting enzyme and the amyloid precursor protein are distinct from tumour necrosis factor-a convertase. FEBS Lett 431, 63-65.
31. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F (1999) Constitutive and regulated α-secretase cleavage of Alzheimer's amyloid precursor proteinbyadisintegrinmetalloprotease. Proc Natl Acad Sci USA 96, 3922-3927.
32. Buxbaum JD, Liu K-N, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP, Black RA (1998) Evidence that tumor necrosis factor a converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273, 27765-27767.
33. Allinson TM, Parkin ET, Condon TP, Schwager SL, Sturrock ED, Turner AJ, Hooper NM (2004) The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein. Eur J Biochem 271, 2539-2547.
34. Van Nostrand WE, Wagner SL, Shankle WD, Farrow JS, Dick M, Rozemuller JM, Kuiper MA, Wolters EC, Zimmerman J, Cotman CW, Cunningham DD (1992) Decreased levels of soluble amyloid β-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sci USA 89, 2552-2555.
35. Lannfelt L, Basun H, Wahlund L-O, Rowe BA, Wagner SL (1995) Decreased α-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Nature Med 1, 829-832.
36. Colciaghi F,Borroni B, Pastorino L,Marcello E,Zimmermann M, Cattabeni F, Padovani A, Di Luca M (2002) α-Secretase ADAM10 as well as aAPPs is reduced in platelets and CSF of Alzheimer disease patients. Mol Med 8, 67-74.
37. Nielsen HM, Londos E, Minthon L, Janciauskiene SM (2007) Soluble adhesion molecules and angiotensin-converting enzyme in dementia. Neurobiol Dis 26, 27-35.
38. Arregui A, Perry EK, Rossor M, Tomlinson BE (1982) An-giotensin converting enzyme in Alzheimer's disease: increased activity in candate nucleus and cortical areas. J Neurochem 38, 1490-1492.
39. Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C, Muller-Spahn F (2001) Cortical alterations of an-giotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging 22, 541-546.
40. Barnes NM, Cheng CHK, Costall B, Naylor RJ, Williams TJ, Wischik CM (1991) Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease. Eur J Pharmacol 200, 289-292.
41. Miners JS, Ashby E, Van Helmond Z, Chalmers KA, Palmer LE, Love S,KehoePG(2008) Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 34, 181-193.
42. Zubenko GS, Marquis JK, Volicer L, Direnfeld LK, Langlais PJ, NixonRA (1986) Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study. Biol Psychiatry 21, 1365-1381.
43. Ohrui T, Matsui T, Yamaya M, Arai H, Ebihara S, Maruyama M, Sasaki H(2004) Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc 52, 649-650.
44. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, Chalmers J (2003) Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163, 1069-1075.
45. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, Tschanz JT, Mayer LS, Welsh-Bohmer KA, Breitner JC (2006) Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 63, 686-692.
46. Kehoe PG, Wilcock GK (2007) Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 6, 373-378.